Johnson & Johnson (JNJ) said Monday that Health Canada authorized lazcluze in combination with rybrevant as a first-line treatment for certain patients with advanced non-small cell lung cancer.
The company said the approval is based on a phase 3 study of the combination in patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 L858R substitution mutations.
The trial showed that the combination reduced the risk of disease progression or death by 30% compared with osimertinib, with a median progression-free survival of 23.7 months versus 16.6 months, according to Johnson & Johnson. The median duration of response was 25.8 months, nine months longer than with osimertinib, the company said.
The drugmaker said its Janssen unit holds marketing authorization for lazcluze and rybrevant in Canada.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.